Service Corp. (SCI) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.82%. A quarter ago, it was expected that this funeral home and cemetery operator would post earnings of $0.84 per share when it actually produced earnings of $0.88, delivering a surprise of +4.76%.Over the last fou ...

Exhibit 99.1 SERVICE CORPORATION INTERNATIONAL ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS, CONFIRMS 2025 EARNINGS MIDPOINT AND RAISES 2025 CASH FLOW GUIDANCE Conference call on Thursday, October 30, 2025, at 8:00 a.m. Central Time. HOUSTON, Texas, October 29, 2025 . . . Service Corporation International (NYSE: SCI), the largest provider of deathcare products and services in North America, today reported results for the third quarter of 2025. Third Quarter Highlights: Tom Ryan, the Company's Chairman and ...

Accessibility StatementSkip Navigation Conference call on Thursday, October 30, 2025, at 8:00 a.m. Central Time. HOUSTON, Oct. 29, 2025 Service Corporation International (NYSE: SCI), the largest provider of deathcare products and services in North America, today reported results for the third quarter of 2025. Third  Quarter Highlights: Tom Ryan, the Company's Chairman and CEO, commented on the third quarter performance: "We are proud to report adjusted earnings per share of $0.87 and net cash provided by ...

For those looking to find strong Consumer Staples stocks, it is prudent to search for companies in the group that are outperforming their peers. Service Corp. (SCI) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Consumer Staples peers, we might be able to answer that question.Service Corp. is a member of our Consumer Staples group, which inc ...

Key Takeaways Service Corporation benefits from strong leadership in the recession-resilient deathcare industry. A broad network and balanced at-need and pre-need services provide steady recurring revenues. Focused investments in cemeteries, facilities and acquisitions strengthen SCI's growth foundation. Service Corporation International (SCI) is likely to register an increase in both top and bottom lines when it reports third-quarter 2025 earnings on Oct. 29. The Zacks Consensus Estimate for Service Corpor ...

Core Insights - CEL-SCI Corporation is scheduled to present its strategic roadmap for Multikine at the LD Micro "Main Event" Investor Conference on October 21, 2025 [1][2] Company Overview - CEL-SCI Corporation is a clinical stage cancer immunotherapy company focused on enhancing the immune system's ability to target tumors before surgical interventions [3] - The company operates in Vienna, Virginia, and near Baltimore, Maryland [5] Product Information - Multikine (Leukocyte Interleukin, Injection) is a first-line cancer therapy that has been administered to over 740 patients and has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck [4] - The FDA has approved CEL-SCI to conduct a confirmatory Registration Study for Multikine, which will enroll 212 patients with newly diagnosed locally advanced resectable head and neck cancer [4] - The target patient population for this study is estimated to represent about 100,000 patients annually [4]

Core Insights - Crude Value Insights provides an investment service and community focused on the oil and natural gas sector, emphasizing cash flow and the companies that generate it, which leads to value and growth prospects with real potential [1] Company Offerings - Subscribers gain access to a model account with over 50 stocks, in-depth cash flow analyses of exploration and production (E&P) firms, and live chat discussions about the sector [1] Promotional Offer - A two-week free trial is available for new subscribers, allowing them to explore the services related to oil and gas investments [2]

Top U.S. Marijuana Stocks to Watch in October 2025The U.S. cannabis industry continues to show remarkable strength as legalization momentum grows nationwide. Analysts project the market will exceed $45 billion by 2025, reflecting strong consumer demand and expanding state-level access. In addition, the cannabis sector supports over 400,000 full-time jobs and contributes billions in tax revenue each year. Recent headlines suggest the federal government may soon revisit reclassification, fueling optimism amon ...

Accessibility StatementSkip Navigation HOUSTON, Oct. 16, 2025 /PRNewswire/ -- Service Corporation International (NYSE:Â SCI) announced it expects to issue a press release with financial results for the third quarter 2025 on Wednesday, October 29, 2025. A conference call will be hosted by SCI Management on Thursday, October 30, 2025. Details of the conference call are as follows:Â (877) 344-7529, International callers at (412) 317-0088, Code – 5177797 available through SERVICE CORPORATION INTERNATIONAL ANNOU ...

Core Viewpoint - CEL-SCI Corporation is set to present its strategic roadmap for the development of Multikine at the LD Micro "Main Event" Investor Conference on October 21, 2025 [1][2]. Company Overview - CEL-SCI Corporation is a clinical stage cancer immunotherapy company focused on enhancing the immune system's ability to target tumors before surgical interventions [3]. - The company operates in Vienna, Virginia, and near Baltimore, Maryland [5]. Product Information - Multikine (Leukocyte Interleukin, Injection) is a first-line cancer therapy that has been administered to over 740 patients and has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck [4]. - A completed randomized controlled Phase 3 study involving 928 patients has led to FDA approval for a confirmatory Registration Study, which will enroll 212 patients with newly diagnosed locally advanced resectable head and neck cancer [4]. - The target patient population for this study is approximately 100,000 patients annually, specifically those with no lymph node involvement and low PD-L1 tumor expression [4].